Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 41, Issue 2, 1998, Pages 344-353

  Suzuki, Noboru ^a   Ichino, Motohide ^a   Mihara, Shoji ^a   Kaneko, Sakae ^a   Sakane, Tsuyoshi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; FAS ANTIGEN; FAS LIGAND;

APOPTOSIS; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; LEUKEMIA CELL LINE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ADOLESCENT; ADULT; ANIMALS; ANTIGENS, CD95; APOPTOSIS; AUTOANTIBODIES; COS CELLS; FAS LIGAND PROTEIN; FEMALE; HUMANS; JURKAT CELLS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTES; MEMBRANE GLYCOPROTEINS; MIDDLE AGED;

EID: 0031910535     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199802)41:2<344::AID-ART19>3.0.CO;2-J     Document Type: Article

References (54)

1. Steinberg AD. Systemic lupus erythematosus: theories of pathogenesis and approach to therapy. Clin Immunol Immunopathol 1994;72:171-6.
2. Tsokos GC. Overview of cellular immune function in systemic lupus erythematosus. In: Lahita RG, editor. Systemic lupus erythematosus. 2nd ed. New York: Churchill Livingstone; 1992. p. 15-50.
3. Tan EM. Auto-antibodies in systemic lupus erythematosus. In: McCarty DJ, Koopman WJ. Arthritis and allied conditions: a textbook of rheumatology. 12th ed. Philadelphia: Lea & Febiger; 1993. p. 1179-99.
4. Woods VL Jr, Zvaifler NJ. Pathogenesis of systemic lupus erythematosus. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB. Textbook of rheumatology. 3rd ed. Philadelphia: WB Saunders; 1989. p. 1077-100.
5. Trauth BC, Klas C, Peters AMJ, Matzku S, Moller P, Falk W, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-5.
6. Suda T, Takahashi T, Goldstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
7. Nagata S. Fas and Fas ligand: a death factor and its receptor. Adv Immunol 1994;57:129-44.
8. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995;181:71-7.
9. Kabelitz D, Pohl T, Pechhold K. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol Today 1993;14:339-40.
10. Dhein J, Walczak H, Baumler C, Debatin K-M, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995;373:438-41.
11. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995;373:441-4.
12. Ju S-T, Panka DJ, Cui H, Ettinger R, El-Khatib M, Sherr DH, et al. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995;373:444-8.
13. Singer GG, Abbas AK. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1994;1:365-71.
14. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991;9:243-69.
15. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995;16:39-43.
16. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76:969-76.
17. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356: 314-7.
18. Russell JH, Rush B, Weaver C, Wang R. Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc Natl Acad Sci U S A 1993;90:4409-13.
19. Elkon KB. Apoptosis in SLE - too little or too much? Clin Exp Rheumatol 1994;12:553-9.
20. Mountz JD, Wu J, Cheng J, Zhou T. Autoimmune disease: a problem of defective apoptosis. Arthritis Rheum 1994;37:1415-20.
21. Rose LM, Latchman DS, Isenberg DA. Bcl-2 and Fas, molecules which influence apoptosis: a possible role in systemic lupus erythematosus? Autoimmunity 1994;17:271-8.
22. Mysler E, Bini P, Drappa J, Ramos P, Friedman SM, Krammer PH, et al. The APO-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 1994;93:1029-34.
23. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-62.
24. Knipping E, Krammer PH, Onel KB, Lehman TJA, Mysler E, Elkon KB. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 1995;38:1735-7.
25. Goel N, Ulrich DT, St. Clair EW, Fleming JA, Lynch DH, Seldin MF. Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum 1995;38:1738-43.
26. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996;98:1107-13.
27. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
28. Brenner CA, Tam AW, Nelson PA, Engleman EG, Suzuki N, Fry KE, et al. Message amplification phenotyping (MAPPing): a technique to simultaneously measure multiple mRNAs from small numbers of cells. Biotechniques 1989;7:1096-103.
29. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1989.
30. Harlow E, Lane D. Antibodies: a laboratory manual. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1988.
31. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
32. Kaneko S, Suzuki N, Koizumi H, Yamamoto S, Sakane T. Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen specific T cell clones. Clin Exp Immunol 1997; 109: 185-93.
33. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
34. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995;182:1777-83.
35. Sato T, Irie S, Kitada S, Reed JC. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995;268:411-5.
36. Klas C, Debatin KM, Jonker RR, Krammer PH. Activation interferes with APO-1 pathway in mature human T cells. Int Immunol 1993;5:625-30.
37. Elkon KB. Autoantibodies in SLE. In: Dieppe PA, Klippel JH, editors. Textbook of rheumatology. London: Mosby Publishing; 1994. p. 1-10.
38. Ichino M, Suzuki N, Sumita K, Kaneko S, Sakane T. Aberrant expression of Fas ligand on lymphocytes in patients with systemic lupus erythematosus [abstract]. Arthritis Rheum 1995;38 Suppl 9:S210.
39. Winfield JB, Mimura T. Antilymphocyte autoantibodies. In: Lahita RG, editor. Systemic lupus erythematosus. 2nd ed. New York: Churchill Livingstone; 1992. p. 293-304.
40. Sakane T, Steinberg AD, Reeves JP, Green I. Studies of immune functions of patients with systemic lupus erythematosus: complement-dependent immunoglobulin M anti-thymus-derived cell antibodies preferentially inactivate suppressor cells. J Clin Invest 1979;63:954-65.
41. Honda M, Sakane T, Steinberg AD, Kotani H, Tsunematsu T, Moriyama K, et al. Studies of immune functions of patients with systemic lupus erythematosus: antibodies to desialized, rather than intact, T cells preferentially bind to and eliminate suppressor effector T cells. J Clin Invest 1982;69:940-9.
42. Sakane T, Steinberg AD, Reeves JP, Green I. Studies of immune functions of patients with systemic lupus erythematosus: T-cell subsets and antibodies to T-cell subsets. J Clin Invest 1979;64: 1260-9.
43. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989;7:445-80.
44. Tanaka M, Suda T, Yatomi T, Nakamura N, Nagata S. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J Immunol 1997;158:2303-9.
45. Martinez-Lorenzo MJ, Alava MA, Anel A, Pineiro A, Naval J. Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells. Immunology 1996;89:511-7.
46. Suda T, Tanaka M, Miwa K, Nagata S. Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand. J Immunol 1996;157:3918-24.
47. Sato K, Kimura F, Nakamura Y, Murakami H, Yoshida M, Tanaka M, et al. An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand. Br J Haematol 1996;94:379-82.
48. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, et al. Fas ligand in human serum. Nat Med 1996;2:317-22.
49. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J 1995;14:1129-35.
50. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-46.
51. Sneller MC, Straus SE, Jaffe ES, Jaffe JS, Fleisher TA, Stetler Stevenson M, et al. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest 1992; 90:334-41.
52. Sneller MC, Wang J, Dale JK, Strober W, Middelton LA, Choi Y, et al. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 1997;89:1341-8.
53. Smith HR, Steinberg AD. Autoimmunity: a perspective. Annu Rev Immunol 1983;1:175-210.
54. Suzuki N, Harada T, Mihara S, Sakane T. Characterization of a germline Vk gene encoding cationic anti-DNA antibody and role of receptor editing for development of the autoantibody in patients with systemic lupus erythematosus. J Clin Invest 1996;98: 1843-50.